FNN / Shaw's broker presentation by Peta, page-2

I found the following that was discussed during Peta's presentation of interest:

- Comments in regards to the company currently in dialogue with 3 insurance businesses in Australian and one of the largest in the world,

- Peta referring to the current patient population growing from 25,000 to 50,000. This is no doubt off the recent uplift in the corporate product coming to market and significant contract wins that Peta and her team have achieved. It will be good to get an update from the business around this and what this means vs last year, project growth rate, Illuminate product launch / customer wins,

- Finally Peta discussing the upcoming FDA submission, with the business looking to use the 'fast tracked' process. I understand this option is available to a certain criteria of submission. Hopefully this business will explain this further when they make the formal FDA submission and inform the market of this.